Born to Kill: NK Cells Go to War against Cancer

Erik Wennerberg; Lorenzo Galluzzi

doi:10.1016/j.trecan.2018.12.005

Born to Kill: NK Cells Go to War against Cancer

Erik Wennerberg, Lorenzo Galluzzi

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.

Original language	English
Pages (from-to)	143-145
Number of pages	3
Journal	Trends in Cancer
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.trecan.2018.12.005
State	Published - Mar 2019
Externally published	Yes

Keywords

NKG2A
NKG2D
PD-1
durvalumab
immune checkpoint blockers
immunotherapy
monalizumab
pembrolizumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2018.12.005

Cite this

@article{62e828c255d54f73abd3532e3331e9d8,

title = "Born to Kill: NK Cells Go to War against Cancer",

abstract = "Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.",

keywords = "NKG2A, NKG2D, PD-1, durvalumab, immune checkpoint blockers, immunotherapy, monalizumab, pembrolizumab",

author = "Erik Wennerberg and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = mar,

doi = "10.1016/j.trecan.2018.12.005",

language = "English",

volume = "5",

pages = "143--145",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Born to Kill

T2 - NK Cells Go to War against Cancer

AU - Wennerberg, Erik

AU - Galluzzi, Lorenzo

PY - 2019/3

Y1 - 2019/3

N2 - Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.

AB - Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.

KW - NKG2A

KW - NKG2D

KW - PD-1

KW - durvalumab

KW - immune checkpoint blockers

KW - immunotherapy

KW - monalizumab

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85059756463&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2018.12.005

DO - 10.1016/j.trecan.2018.12.005

M3 - Short survey

C2 - 30898260

AN - SCOPUS:85059756463

SN - 2405-8033

VL - 5

SP - 143

EP - 145

JO - Trends in Cancer

JF - Trends in Cancer

IS - 3

ER -

Born to Kill: NK Cells Go to War against Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this